Volume 14 Issue 2
Mar.  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(2): 257-264
Zou Zhiyu, Chen Song, Chang Sheng, et al. Early application of tacrolimus extended-release capsule after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 257-264. doi: 10.3969/j.issn.1674-7445.2023.02.012
Citation: Zou Zhiyu, Chen Song, Chang Sheng, et al. Early application of tacrolimus extended-release capsule after kidney transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(2): 257-264. doi: 10.3969/j.issn.1674-7445.2023.02.012
shu

Early application of tacrolimus extended-release capsule after kidney transplantation

doi: 10.3969/j.issn.1674-7445.2023.02.012

  • Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

More Information
  • Corresponding author: Zhang Weijie, Email: wjzhangtj@126.com
  • Received Date: 2022-10-13
    Available Online: 2023-03-15
  • Publish Date: 2023-03-15
    Abstract
  •   Objective  To evaluate the efficacy and safety of tacrolimus extended-release (Tac-ER) in the early stage after kidney transplantation.  Methods  Clinical data of 68 recipients undergoing kidney transplantation from 34 pairs of renal allografts were retrospectively analyzed. Two recipients who received bilateral kidneys from the same donor were treated with Tac-ER (Tac-ER group) and tacrolimus immediate-release (Tac-IR) (Tac-IR group) as one of the basic immunosuppressant. The changes of tacrolimus dosage and blood concentration, intra-patient variability (IPV), renal function, incidence of acute rejection, recipient and allograft survival rates and adverse events were statistically compared between two groups.  Results  The average daily dose of tacrolimus in the Tac-ER group was significantly higher than that in the Tac-IR group (F=8.386, P=0.005). In the Tac-ER group, the mean trough concentration at postoperative 4 d was (6.14±4.04) ng/mL, did not reach the target concentration, significantly lower than (9.41±5.47) ng/mL in the Tac-IR group (F=7.854, P=0.007). In the Tac-ER group, the IPV of trough concentration of tacrolimus within postoperative 1 month was significantly higher than that in the Tac-IR group (0.44±0.15 vs. 0.36±0.12, P=0.032). At postoperative 6 months, there was no significant difference in the renal function between two groups [serum creatinine level was (126±26) μmol/L vs. (120±28) μmol/L, and the estimated glomerular filtration rate was (56±13) mL/(min·1.73 m2) vs. (60±15) mL/(min·1.73 m2), both P > 0.05]. The allograft and recipient survival rates were 100% in both groups. The incidence of acute rejection within postoperative 1 month was 18% in the Tac-ER group and 3% in the Tac-IR group, with no significant difference (P > 0.05). The overall incidence of adverse events was 94% in the Tac-ER group and 97% in the Tac-IR group, with no significant difference (P > 0.05).  Conclusions  The efficacy and safety of Tac-ER are equivalent to those of Tac-IR, whereas a higher dose of Tac-ER should be orally given to reach the blood concentration similar to that of Tac-IR. During early-stage drug treatment, Tac-ER should be orally given before kidney transplantation or inittally with loading dose, aiming to increase the systemic exposure to tacrolimus early after kidney transplantation and prevent acute rejection caused by insufficient exposure.

     

    • FullText(HTML)
  • loading
    • References(35)
  • [1]
    LENTINE KL, SMITH JM, HART A, et al. OPTN/SRTR 2020 annual data report: kidney[J]. Am J Transplant, 2022, 22(Suppl 2): 21-136. DOI: 10.1111/ajt.16982.
    [2]
    HART A, LENTINE KL, SMITH JM, et al. OPTN/SRTR 2019 annual data report: kidney[J]. Am J Transplant, 2021, 21(Suppl 2): 21-137. DOI: 10.1111/ajt.16502.
    [3]
    HART A, SMITH JM, SKEANS MA, et al. OPTN/SRTR 2018 annual data report: kidney[J]. Am J Transplant, 2020, 20(Suppl 1): 20-130. DOI: 10.1111/ajt.15672.
    [4]
    GONDOS A, DÖHLER B, BRENNER H, et al. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes[J]. Transplantation, 2013, 95(2): 267-274. DOI: 10.1097/TP.0b013e3182708ea8.
    [5]
    NEUBERGER JM, BECHSTEIN WO, KUYPERS DR, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) group[J]. Transplantation, 2017, 101(4S Suppl 2): S1-S56. DOI: 10.1097/TP.0000000000001651.
    [6]
    VADCHARAVIVAD S, SAENGRAM W, PHUPRADIT A, et al. Once-daily versus twice-daily tacrolimus in kidney transplantation: a systematic review and meta-analysis of observational studies[J]. Drugs, 2019, 79(18): 1947-1962. DOI: 10.1007/s40265-019-01217-7.
    [7]
    OH CK, BANG JB, KIM SJ, et al. Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: a prospective cohort study[J]. Asian J Surg, 2020, 43(6): 660-667. DOI: 10.1016/j.asjsur.2019.07.011.
    [8]
    HO B, BHAGAT H, SCHWARTZ JJ, et al. Real-world study of once-daily, extended-release tacrolimus versus twice-daily, immediate-release tacrolimus in kidney transplantation: clinical outcomes and healthcare resource utilization[J]. Adv Ther, 2019, 36(6): 1465-1479. DOI: 10.1007/s12325-019-00904-x.
    [9]
    SÁNCHEZ FRUCTUOSO A, RUIZ JC, FRANCO A, et al. Effectiveness and safety of the conversion to MeltDose® extended-release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: a retrospective study[J]. Clin Transplant, 2020, 34(1): e13767. DOI: 10.1111/ctr.13767.
    [10]
    LANG S, SHARMA A, FOSTER B, et al. Age and sex determine conversion from immediate-release to extended-release tacrolimus in a multi-center cohort of Canadian pediatric renal transplant recipients[J]. Pediatr Transplant, 2021, 25(5): e13959. DOI: 10.1111/petr.13959.
    [11]
    FERNANDEZ RIVERA C, CALVO RODRÍGUEZ M, POVEDA JL, et al. Bioavailability of once-daily tacrolimus formulations used in clinical practice in the management of de novo kidney transplant recipients: the better study[J]. Clin Transplant, 2022, 36(3): e14550. DOI: 10.1111/ctr.14550.
    [12]
    OBERBAUER R, BESTARD O, FURIAN L, et al. Optimization of tacrolimus in kidney transplantation: new pharmacokinetic perspectives[J]. Transplant Rev (Orlando), 2020, 34(2): 100531. DOI: 10.1016/j.trre.2020.100531.
    [13]
    VONDRAK K, PARISI F, DHAWAN A, et al. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus[J]. Clin Transplant, 2019, 33(10): e13698. DOI: 10.1111/ctr.13698.
    [14]
    TABER DJ, POSADAS-SALAS A, SU Z, et al. Preliminary assessment of safety and adherence to a once-daily immunosuppression regimen in kidney transplantation: results of a randomized controlled pilot study[J]. Clin Transplant, 2020, 34(4): e13844. DOI: 10.1111/ctr.13844.
    [15]
    SAPIR-PICHHADZE R, WANG Y, FAMURE O, et al. Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure[J]. Kidney Int, 2014, 85(6): 1404-1411. DOI: 10.1038/ki.2013.465.
    [16]
    TAN T, BUNNAPRADIST S. Comparing the pharmacokinetics of extended-release tacrolimus (LCP-TAC) to immediate-release formulations in kidney transplant patients[J]. Expert Opin Drug Metab Toxicol, 2021, 17(10): 1175-1186. DOI: 10.1080/17425255.2021.1974399.
    [17]
    SILVA HT JR, YANG HC, MEIER-KRIESCHE HU, et al. Long-term follow-up of a phase Ⅲ clinical trial comparing tacrolimus extended-release/MMF, tacrolimus/MMF, and cyclosporine/MMF in de novo kidney transplant recipients[J]. Transplantation, 2014, 97(6): 636-641. DOI: 10.1097/01.TP.0000437669.93963.8E.
    [18]
    JANUARY SE, HAGOPIAN JC, NESSELHAUF NM, et al. Clinical experience with extended-release tacrolimus in older adult kidney transplant recipients: a retrospective cohort study[J]. Drugs Aging, 2021, 38(5): 397-406. DOI: 10.1007/s40266-021-00842-w.
    [19]
    HIRAMITSU T, TOMOSUGI T, FUTAMURA K, et al. Optimal blood levels of (extended-release) tacrolimus in living donor kidney transplantation to prevent de novo donor-specific antibody production: a retrospective cohort study[J]. Int Immunopharmacol, 2021, 91: 107038. DOI: 10.1016/j.intimp.2020.107038.
    [20]
    GUIRADO L, CANTARELL C, FRANCO A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients[J]. Am J Transplant, 2011, 11(9): 1965-1971. DOI: 10.1111/j.1600-6143.2011.03571.x.
    [21]
    HIDAKA Y, GOTO N, YAMANAGA S, et al. Two-year outcomes of low-exposure extended-release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: a multi-center randomized controlled trial[J]. Clin Transplant, 2022, 36(6): e14655. DOI: 10.1111/ctr.14655.
    [22]
    JASIAK-PANEK NM, WENZLER E, PATEL S, et al. A randomized, open-label pharmacokinetic trial of tacrolimus extended-release dosing in obese de novo kidney transplant recipients[J]. Clin Transplant, 2019, 33(8): e13640. DOI: 10.1111/ctr.13640.
    [23]
    KIM YH, CHIANG YJ, KIM SJ, et al. Safety and efficacy of reduced prolonged-release tacrolimus exposure in de novo kidney transplantation: a randomized, open-label, pilot study in Asia-OPTIMIZE study[J]. Transplant Direct, 2019, 5(4): e340. DOI: 10.1097/TXD.0000000000000877.
    [24]
    王梓宇, 王洪阳, 王清海, 等. 转换使用他克莫司缓释胶囊对肾移植受者治疗有效性及安全性的影响[J]. 精准医学杂志, 2022, 37(5): 400-403. DOI: 10.13362/j.jpmed.202205006.

    WANG ZY, WANG HY, WANG QH, et al. Effect of conversion to tacrolimus sustained-release capsules on treatment efficacy and safety in kidney transplant recipients[J]. J Precis Med, 2022, 37(5): 400-403. DOI: 10.13362/j.jpmed.202205006.
    [25]
    POSADAS SALAS MA, SRINIVAS TR. Update on the clinical utility of once-daily tacrolimus in the management of transplantation[J]. Drug Des Devel Ther, 2014, 8: 1183-1194. DOI: 10.2147/DDDT.S55458.
    [26]
    DEL BELLO A, GAIBLE C, LONGLUNE N, et al. Tacrolimus intrapatient variability after switching from immediate or prolonged-release to extended-release formulation, after an organ transplantation[J]. Front Pharmacol, 2021, 12: 602764. DOI: 10.3389/fphar.2021.602764.
    [27]
    CASSUTO E, PAGEAUX GP, CANTAROVICH D, et al. Adherence to and acceptance of once-daily tacrolimus after kidney and liver transplant: results from OSIRIS, a French observational study[J]. Transplantation, 2016, 100(10): 2099-2106. DOI: 10.1097/TP.0000000000001307.
    [28]
    BUNTHOF KLW, AL-HASSANY L, NAKSHBANDI G, et al. A randomized crossover study comparing different tacrolimus formulations to reduce intrapatient variability in tacrolimus exposure in kidney transplant recipients[J]. Clin Transl Sci, 2022, 15(4): 930-941. DOI: 10.1111/cts.13206.
    [29]
    STIFFT F, STOLK LM, UNDRE N, et al. Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation[J]. Transplantation, 2014, 97(7): 775-780. DOI: 10.1097/01.TP.0000437561.31212.0e.
    [30]
    XIE Q, XIANG Q, LIU Z, et al. Effects of CPY3A5 genetic polymorphisms on the pharmacokinetics of extended release and immediate-release tacrolimus formulations in renal transplant recipients: a systematic review and meta-analysis[J]. Curr Drug Metab, 2021, 22(10): 758-771. DOI: 10.2174/1389200222666210825160021.
    [31]
    THÖLKING G, FILENSKY B, JEHN U, et al. Increased renal function decline in fast metabolizers using extended-release tacrolimus after kidney transplantation[J]. Sci Rep, 2021, 11(1): 15606. DOI: 10.1038/s41598-021-95201-5.
    [32]
    陈攀, 傅茜, 李晶洁, 等. CYP3 A5基因型对中国肾移植术后患者体内他克莫司缓释剂型药动学参数的影响[J]. 中国药理学通报, 2016, 32(11): 1592-1595. DOI: 10.3969/j.issn.1001-1978.2016.11.021.

    CHEN P, FU Q, LI JJ, et al. Impact of CYP3 A5 genetic polymorphism on modified releasing tacrolimus pharmacokinetics in Chinese renal transplant recipients[J]. Chin Pharm Bull, 2016, 32(11): 1592-1595. DOI: 10.3969/j.issn.1001-1978.2016.11.021.
    [33]
    石丽娟, 胡津鹏, 陈妍, 等. CYP3A5基因多态性对肾移植受者他克莫司谷浓度及肾功能恢复的影响[J]. 中国处方药, 2022, 20(6): 22-24. DOI: 10.3969/j.issn.1671-945X.2022.06.010.

    SHI LJ, HU JP, CHEN Y, et al. Effects of CYP3A5 gene polymorphism on the trough concentration of tacrolimus and the recovery of renal function in renal transplant recipients[J]. J China Prescr Drug, 2022, 20(6): 22-24. DOI: 10.3969/j.issn.1671-945X.2022.06.010.
    [34]
    王世磊, 丰贵文. 他克莫司缓释胶囊在CYP3A5不同基因型肾移植受者中浓度/剂量值的差异[J]. 河南医学研究, 2021, 30(15): 2708-2711. DOI: 10.3969/j.issn.1004-437X.2021.15.006.

    WANG SL, FENG GW. Differences of concentration/dose of tacrolimus sustained-release capsules in kidney transplant recipients with different CYP3A5 genotypes[J]. Henan Med Res, 2021, 30(15): 2708-2711. DOI: 10.3969/j.issn.1004-437X.2021.15.006.
    [35]
    张恩瑶, 向倩, 谢秋芬, 等. CYP3A5基因多态性的他克莫司个体化用药临床研究分析[J]. 中国临床药理学杂志, 2022, 38(8): 864-868. DOI: 10.13699/j.cnki.1001-6821.2022.08.024.

    ZHANG EY, XIANG Q, XIE QF, et al. Clinical therapy analysis of individualized medication of tacrolimus based on CYP3 A5 gene polymorphism[J]. Chin J Clin Pharm, 2022, 38(8): 864-868. DOI: 10.13699/j.cnki.1001-6821.2022.08.024.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(5)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (365) PDF downloads(101) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return